Riptidez LLC
Eloralintide 10mg
Eloralintide 10mg
Create a research account to view pricing
Login to view pricing✔ Flat $10 U.S. shipping • Ships within 24 hours
Login to purchase research materials
Login to purchase✔ For laboratory research use only ✔ Ships within 24 hours (U.S. fulfillment) ✔ Secure checkout & discreet packaging ✔ ✔ Clearly labeled vial with quantity displayed Not for human or veterinary use
Eloralintide 10 mg | Research Peptide
Exploring a Different Pathway in Metabolic Research.
Eloralintide (LY3841136) is an investigational selective amylin receptor agonist attracting scientific interest for its role in appetite signaling, satiety, and metabolic regulation.
While GLP-1 research has received significant attention, eloralintide represents a different approach by targeting the amylin signaling pathway.
What Is Eloralintide?
Eloralintide is an investigational peptide designed to preferentially activate the amylin-1 receptor (AMY1R).
Amylin is a naturally occurring hormone released alongside insulin after eating. It helps communicate signals related to fullness and food intake.
By studying this pathway, researchers are gaining a better understanding of the complex signals involved in metabolic regulation.
Areas of Scientific Interest
- Amylin receptor activity and signaling
- Appetite and satiety pathways
- Metabolic regulation
- Body-weight regulation in clinical research
- Interactions with incretin signaling pathways
How Is Eloralintide Different from GLP-1?
Both GLP-1 and amylin pathways are involved in metabolic signaling, but they operate through different receptors.
GLP-1 receptor agonists target the GLP-1 receptor, while eloralintide preferentially targets AMY1R. Researchers are investigating these pathways individually and in combination to better understand their biological effects.
Current Research
Published Phase 2 clinical research has investigated eloralintide in adults with obesity or overweight. Research has examined body-weight outcomes, tolerability, and metabolic measures.
Eloralintide has advanced into Phase 3 clinical investigation and remains an investigational compound without FDA approval.
Product Specifications
- Compound: Eloralintide
- Research Identifier: LY3841136
- Nominal Amount: 10 mg per vial
- Classification: Selective Amylin Receptor Agonist
- Research Area: Metabolic Signaling
- Intended Application: Laboratory Research Only
Research Use Only
FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.
Eloralintide is an investigational compound. It is not FDA-approved. This product is not intended for human consumption, clinical use, self-administration, or veterinary applications. It is not intended to diagnose, treat, cure, or prevent any disease.
Explore More Research
Interested in learning more about metabolic signaling and peptide research?
Share
